“Eighty-five companies applied. From these, a judging panel drawn from industry and the investing community selected a cohort of 12: four “emerging,” or earlier-stage, startups, and eight who had advanced their technologies further along the path to market.” – QB3/Cision PR Newswire
Nanotein Chosen as a Top Emerging Biotech by QB3 at Their Biotech/Biopharma Pitch Summit